The effects of MLT and CGP 52 608 (the selective ligand for nuclear RZR/ROR receptors) were comparable with suppression caused by methotrexate.

Fatigue, sleep, and depressive symptoms are more prevalent in women with cancer than a cancer-free comparison group.

Light plays on nocturnal melatonin production and the incidence of breast cancer.

Little evidence that sleeping few hours per night was associated with breast cancer risk.

No abstract available.

Maximum values of 5-year survival were registered in those diagnosed with cancer in winter or summer, while those diagnosed in spring or fall had unfavorable prognosis.

Melatonin and estrogen in BCF predicted growth inhibition and stimulation. Biological monitoring of BCF may help identify women with GCBD at greatest risk for breast cancer development.

The exposure to light at night (LAN) and anthropogenic electric and magnetic fields (EMFs) is related to the increased incidence of breast cancer and childhood leukaemia via melatonin disruption.

Increased breast tumorigenesis has been reported in melatonin-suppressed experimental models.

Intense exercise-induced stress enhances mammary carcinogenesis through the involvement of adrenaline and prolactin, also confirmed a role of melatonin as a therapeutic aid against breast cancer in general.